Several clinical trials assessing the activity of PIK3 inhibitors and AKT inhibitors in endometrial cancer have been done, however current data is inconclusive or limited by toxicity profiles and would warrant further trials (28). This evidence concerns the gene PIK3CG and endometrial cancer.